MX2009013804A - Inhibidores novedosos de transcriptasa inversa de vih. - Google Patents

Inhibidores novedosos de transcriptasa inversa de vih.

Info

Publication number
MX2009013804A
MX2009013804A MX2009013804A MX2009013804A MX2009013804A MX 2009013804 A MX2009013804 A MX 2009013804A MX 2009013804 A MX2009013804 A MX 2009013804A MX 2009013804 A MX2009013804 A MX 2009013804A MX 2009013804 A MX2009013804 A MX 2009013804A
Authority
MX
Mexico
Prior art keywords
reverse transcriptase
transcriptase inhibitors
hiv reverse
novel hiv
compounds
Prior art date
Application number
MX2009013804A
Other languages
English (en)
Inventor
Choung U Kim
Lianhong Xu
Michael L Mitchell
Hongyan Guo
Ill Young Lee
Gerry Rhodes
Jong Chan Son
Original Assignee
Korea Res Inst Chem Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Chem Tech filed Critical Korea Res Inst Chem Tech
Publication of MX2009013804A publication Critical patent/MX2009013804A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a los compuestos de la Fórmula (I) o una sal, solvato, éster y/o fosfonato farmacéuticamente aceptable del mismo, las composicines que contiene dichos compuestos métodos terapéuticos que incluyen la administración de dichos compuestos.
MX2009013804A 2007-06-29 2008-06-26 Inhibidores novedosos de transcriptasa inversa de vih. MX2009013804A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93775607P 2007-06-29 2007-06-29
US95967607P 2007-07-16 2007-07-16
PCT/US2008/007925 WO2009005674A2 (en) 2007-06-29 2008-06-26 Novel hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
MX2009013804A true MX2009013804A (es) 2010-02-03

Family

ID=39790161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013804A MX2009013804A (es) 2007-06-29 2008-06-26 Inhibidores novedosos de transcriptasa inversa de vih.

Country Status (15)

Country Link
US (2) US8334295B2 (es)
EP (1) EP2167476B1 (es)
JP (1) JP2010532350A (es)
KR (1) KR101551238B1 (es)
CN (1) CN101784532B (es)
AR (1) AR067181A1 (es)
AU (1) AU2008271114A1 (es)
BR (1) BRPI0813269A2 (es)
CA (1) CA2692460A1 (es)
EA (1) EA200971115A1 (es)
ES (1) ES2533863T3 (es)
MX (1) MX2009013804A (es)
TW (1) TW200918507A (es)
WO (1) WO2009005674A2 (es)
ZA (1) ZA201000023B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044037A2 (en) * 2006-07-24 2009-04-08 Gilead Sciences, Inc. Hiv reverse transcriptase inhibitors
US8354421B2 (en) * 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
US8119800B2 (en) 2007-12-21 2012-02-21 Korea Research Institute Of Chemical Technology Processes for preparing HIV reverse transcriptase inhibitors
US8445669B2 (en) * 2008-04-10 2013-05-21 Hamari Chemicals, Ltd. Production process of ethynylthymidine compounds from 5-methyluridine as a starting material
KR20110112844A (ko) 2009-01-26 2011-10-13 한국화학연구원 Hiv 역전사효소 억제제의 제조 방법
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
ES2516916T3 (es) 2010-01-28 2014-10-31 Mapi Pharma Limited Procedimiento para la preparación de darunavir e intermedios de darunavir
EP2776405A1 (en) 2011-11-11 2014-09-17 Pfizer Inc 2-thiopyrimidinones
WO2013177243A1 (en) 2012-05-23 2013-11-28 Bristol-Myers Squibb Company Sulfilimine and sulphoxide methods for producing festinavir
CA2897444A1 (en) * 2013-01-08 2014-07-17 Genzyme Corporation Use of inos inhibitors to increase viral yield in culture
US20160060252A1 (en) 2013-04-16 2016-03-03 Bristol-Myers Squibb Company 5-methyluridine method for producing festinavir
WO2014201122A1 (en) 2013-06-13 2014-12-18 Bristol-Myers Squibb Company Tert-butyl-sulphoxide method for producing festinavir
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
WO2016178113A1 (en) 2015-05-05 2016-11-10 Pfizer Inc. 2-thiopyrimidinones
JP2018536001A (ja) 2015-12-04 2018-12-06 ヴィーブ ヘルスケア ユーケー リミテッド イソインドリン誘導体
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
AR109950A1 (es) * 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN106831608A (zh) * 2017-02-16 2017-06-13 江苏艾迪药业有限公司 一种化合物的新晶型及其制备方法与应用
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN115536596A (zh) * 2022-11-08 2022-12-30 巨鑫生物制药股份有限公司 一种acc007中间体的制备方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126148A1 (en) * 1971-05-26 1972-12-07 Farbenfabriken Bayer Ag, 5090 Leverkusen Prepn of uracil derivs - useful as plant - protection agents and their inters
DE2142317A1 (de) * 1971-08-24 1973-03-01 Bayer Ag Hypnotisches mittel
US4656209A (en) 1982-05-26 1987-04-07 Ciba-Geigy Corporation Chlorinated thermoplastics stabilized with aminouracils
JPS59201057A (ja) 1983-04-18 1984-11-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US4649142A (en) * 1984-06-25 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent
DD283613A5 (de) 1988-03-31 1990-10-17 ��@���������@�������k�� Verfahren zur herstellung von in 6-stellung substituierte acyclopyrimidin-nucleosid-derivaten
WO1989010701A1 (en) 1988-05-05 1989-11-16 Basf Aktiengesellschaft Substances based on uracil-derivates for stimulating growth and reducing fat in animals
US5219869A (en) 1989-05-17 1993-06-15 Nihon Bayer Agrochem K.K. Nitro-substituted heterocyclic compounds
JPH0751567B2 (ja) * 1989-09-29 1995-06-05 三菱化学株式会社 6―置換アシクロピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤
KR0155168B1 (ko) 1989-09-29 1998-11-16 미우라 아끼라 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제
EP0442473B1 (en) 1990-02-15 1998-08-19 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
JP2860689B2 (ja) 1990-03-14 1999-02-24 第一製薬株式会社 ピリミジン誘導体
EP0449726B1 (en) 1990-03-29 1997-06-11 Mitsubishi Chemical Corporation Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient
WO1992000964A1 (en) 1990-07-05 1992-01-23 Nippon Soda Co., Ltd. Amine derivative
JPH04166931A (ja) 1990-10-31 1992-06-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPH04166930A (ja) 1990-10-31 1992-06-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JP2739260B2 (ja) 1991-04-10 1998-04-15 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
AU1994492A (en) 1991-07-22 1993-02-23 Baker Cummins Pharmaceuticals, Inc. Acyclic 6-phenylselenenyl pyrimidine nucleosides
DE4204032A1 (de) 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
DE4204031A1 (de) 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
JPH05289238A (ja) 1992-04-08 1993-11-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPH06135943A (ja) 1992-09-14 1994-05-17 Japan Energy Corp 新規なウラシル誘導体及びそれを有効成分とするアレルギー疾患治療薬
WO1994027975A1 (de) * 1993-05-21 1994-12-08 Pentapharm Ag 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
KR0151811B1 (ko) * 1993-12-21 1998-10-15 강박광 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법
US5889013A (en) 1994-02-28 1999-03-30 Sunkyong Industries Co., Inc. Pyrimidine acyclonucleoside derivatives
JP3264579B2 (ja) 1994-03-18 2002-03-11 扶桑薬品工業株式会社 クラミジア・トラコマチス血清型の鑑別法
JPH083143A (ja) 1994-06-21 1996-01-09 Mitsubishi Chem Corp 6−アラルキル置換ピリミジン誘導体の製造方法
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US6174998B1 (en) 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
JPH0920792A (ja) 1995-07-11 1997-01-21 Soyaku Gijutsu Kenkyusho:Kk ヌクレオチドダイマー
CN1092647C (zh) 1996-02-22 2002-10-16 三进制药株式会社 新抗病毒的取代嘧啶二酮同素碳环核苷衍生物及其制备方法与含有其为活性成分的组合物
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
JPH10130245A (ja) 1996-09-06 1998-05-19 Mitsubishi Chem Corp アシクロヌクレオシドの製造方法
JPH10130244A (ja) 1996-09-06 1998-05-19 Mitsubishi Chem Corp アシクロヌクレオシドの製造方法
MY114466A (en) 1996-09-25 2002-10-31 Crompton Vinyl Additives Gmbh Rigid pvc stabilised with n, n-dimethyl-6-aminouracils
JPH10168068A (ja) 1996-12-05 1998-06-23 Mitsubishi Chem Corp アシクロヌクレオシドの製造方法
ZA98566B (en) 1997-01-31 1998-07-30 Mitsubishi Chem Corp Antiviral agents
JPH11102047A (ja) 1997-09-26 1999-04-13 Fuji Photo Film Co Ltd 熱現像画像形成材料
US5998411A (en) * 1998-03-17 1999-12-07 Hughes Institute Heterocyclic nonnucleoside inhibitors of reverse transcriptase
FR2779722A1 (fr) 1998-06-15 1999-12-17 Expansia Sa Hydrogenation de 6-alpha-alkylcarboxy methylaryl-1,5-dialkyl uracile
FR2779721A1 (fr) 1998-06-15 1999-12-17 Expansia Sa Substitution d'une 1,5-dialkyl uracile en position 6
ES2189300T3 (es) 1998-06-26 2003-07-01 Crompton Vinyl Additives Gmbh Nuevos 6-aminouracilos modificados con nh2 como estabilizadores para polimeros halogenados.
US6177437B1 (en) 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
US6713486B1 (en) 1999-03-04 2004-03-30 Korea Research Institute Of Chemical Technology Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
KR20000065885A (ko) 1999-04-10 2000-11-15 최승주 항바이러스성 피리미딘다이온 유도체 및 그 제조방법
WO2001023363A1 (fr) 1999-09-29 2001-04-05 Sankyo Company, Limited Derives de sulfonamide
JP2001114767A (ja) 1999-10-15 2001-04-24 Sumika Fine Chemicals Co Ltd ピリミジン化合物の製造方法、およびその中間体の製造方法
WO2001079203A1 (en) 2000-04-17 2001-10-25 Basf Aktiengesellschaft Herbicidal 3-heterocyclic substituted benzisothiazole and benzisoxazole compounds
IL148464A0 (en) 2000-05-04 2002-09-12 Basf Ag Uracil substituted phenyl sulfamoyl carboxamides
DE60221794D1 (de) 2001-01-29 2007-09-27 Univ Geneve Pyrimidinische azyklonukleoside, verfahren zur ihrer herstellung und ihre verwendung
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
WO2003029226A1 (en) 2001-09-26 2003-04-10 Basf Aktiengesellschaft Heterocyclyl substituted phenoxyalkyl-, phenylthioalkyl-, phenylaminoalkyl- and phenylalkyl-sulfamoylcarboxamides
AU2003205536A1 (en) 2002-01-11 2003-07-24 Statens Serum Institut Anti-retroviral 5,6-disubstituted acyclopyrimidine nucleoside derivatives
JP2005516094A (ja) 2002-01-31 2005-06-02 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 塩素水と永続的な接触状態にあるポリオレフィンの安定化
BR0309557A (pt) 2002-04-26 2005-03-01 Gilead Sciences Inc Inibidores da transcriptase reversa não nucleosìdeos
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
EP1553949B1 (en) * 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
US7947817B2 (en) 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
AU2004293423A1 (en) 2003-11-21 2005-06-09 University Of Connecticut Heterocyclyl-substituted oxetanes for the treatment of proliferative or infectious diseases
MXPA03011298A (es) 2003-12-08 2005-06-10 Ct Investig Y Estudios Del Ipn Compuestos 5'-nor-1-homo-n-carbonucleosidos y proceso de obtencion de los mismos.
JP2005212143A (ja) 2004-01-27 2005-08-11 Fuji Photo Film Co Ltd 記録材料
WO2006070292A2 (en) 2004-10-12 2006-07-06 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060223834A1 (en) 2005-04-04 2006-10-05 Vasu Nair Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae
KR101237312B1 (ko) * 2006-02-10 2013-03-04 삼진제약주식회사 피리미딘다이온 유도체를 포함하는 c형 간염의 예방 및치료용 약학 조성물
WO2007106450A2 (en) 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
FI20065162A0 (fi) 2006-03-13 2006-03-13 Wallac Oy Terminoivia DNA polymeraasisubstraatteja
EP2044037A2 (en) 2006-07-24 2009-04-08 Gilead Sciences, Inc. Hiv reverse transcriptase inhibitors
CN101016265A (zh) 2007-03-15 2007-08-15 首都医科大学 一种新型hiv-1逆转录酶抑制剂的制备及其用途
US8119800B2 (en) * 2007-12-21 2012-02-21 Korea Research Institute Of Chemical Technology Processes for preparing HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
CN101784532A (zh) 2010-07-21
US8334295B2 (en) 2012-12-18
KR101551238B1 (ko) 2015-09-09
AR067181A1 (es) 2009-09-30
US20110076276A1 (en) 2011-03-31
AU2008271114A1 (en) 2009-01-08
BRPI0813269A2 (pt) 2014-12-30
ES2533863T3 (es) 2015-04-15
CA2692460A1 (en) 2009-01-08
WO2009005674A2 (en) 2009-01-08
US20130078256A1 (en) 2013-03-28
WO2009005674A3 (en) 2009-09-24
KR20100041799A (ko) 2010-04-22
JP2010532350A (ja) 2010-10-07
EP2167476A2 (en) 2010-03-31
TW200918507A (en) 2009-05-01
EA200971115A1 (ru) 2010-04-30
ZA201000023B (en) 2011-04-28
EP2167476B1 (en) 2015-02-25
CN101784532B (zh) 2014-10-22

Similar Documents

Publication Publication Date Title
MX2009013804A (es) Inhibidores novedosos de transcriptasa inversa de vih.
UA95955C2 (ru) Ингибиторы обратной транскриптазы вич
WO2008011117A3 (en) Antiviral protease inhibitors
WO2008011116A3 (en) Aza-peptide protease inhibitors
TW200618804A (en) Phosphonate analogs of HIV inhibitor compounds
GEP20115320B (en) Non-nucleoside reverse transcriptase inhibitors
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
MX2009009920A (es) Inhibidores no nucleosidos de transcriptasa inversa.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
TN2011000400A1 (en) Inhibitors of beta-secretase
GEP20125459B (en) Compounds for inhibiting mitotic progression
SE0400284D0 (sv) Novel compounds
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
WO2008086226A8 (en) Factor xa inhibitors
AR063098A1 (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
TN2010000038A1 (en) Organic compounds
MX2013004162A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1.
TN2013000257A1 (en) Immunosuppressant formulations
IN2012DN02502A (es)
UA103329C2 (ru) Соли соединений-ингибиторов вич

Legal Events

Date Code Title Description
FG Grant or registration